Table 1.
Model | Unstandardized
coefficients |
Standardized
coefficients |
t | P-value | VIF | ||
---|---|---|---|---|---|---|---|
B | SE | Beta | |||||
(Constant) | 74.752 | 28.620 | 2.61 | 0.022 | |||
aSKNA (μV) | 38.443 | 12.869 | 0.646 | 2.99 | 0.011 | 1.695 | |
LVEF (%) | 0.590 | 0.206 | 0.683 | 2.87 | 0.013 | 2.049 | |
Age, years | −0.753 | 0.277 | −0.531 | −2.72 | 0.018 | 1.385 | |
Beta-blocker | −8.506 | 6.419 | −0.227 | −1.33 | 0.208 | 1.060 | |
CCB | 7.784 | 5.936 | 0.247 | 1.31 | 0.213 | 1.289 | |
Male | 4.940 | 6.350 | 0.165 | 0.78 | 0.451 | 1.621 |
Because there were no significant differences in clinical characteristics or demographics between patients with paroxysmal AF as compared with patients with persistent AF, all patients were analyzed together as a single group. R2 = 0.641, adjusted R2 = 0.475. VR = ventricular rate; SE = standard error; VIF = variance inflation factor; aSKNA = average amplitude of skin sympathetic nerve activity; LVEF = left ventricular ejection fraction; CCB = calcium channel blocker.